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Abstract
Background: Adjuvant treatment options for HER2-
positive Early-Stage Breast Cancer (EBC) have grown in re-
cent years. The addition of adjuvant trastuzumab therapy 
for one-year to standard chemotherapy has been shown 
in several Randomized Controlled Trials (RCTs) to improve 
Disease-Free Survival (DFS) and Overall Survival (OS) in pa-
tients with high-risk HER2-positive EBC. This study aimed to 
review the long-term outcome data for patients with HER2-
positive EBC who were treated with adjuvant trastuzumab 
therapy in a designated cancer centre.
Methods: Data included all women diagnosed with HER2-
positive EBC between 1st January 2001 and 31st January 2010 
(N=147). Retrospective evaluation of healthcare records for 
clinical, demographic, and pathologic data was undertaken. 
Most had adjuvant trastuzumab following systemic che-
motherapy (80/147; 54.4%). Kaplan-Meier estimates were 
used to evaluate whether one-year trastuzumab adminis-
tration was associated with improved DFS and OS. Addition-
ally, cohorts were generated by pathologic tumour size and 
lymph node involvement to stratify outcome measures (i.e. 
DFS and OS) by risk features.
Results: Median follow-up was 59.8 months. Patients 
with HER2-positive EBC who received adjuvant trastuzum-
ab demonstrated improved 5-year DFS (75% to 91%; p = 
0.024), and trend for improved OS (74% to 80%; p = 0.103). 
Kaplan-Meier estimates stratified by pathologic tumour size 
based on receipt of trastuzumab revealed that patients with 
tumours ≥ 2.01cm had improved 5-year DFS (66% to 88%; 
p = 0.031), and 5-year OS (66% to 79%; p = 0.134). While 
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Kaplan-Meier estimates stratified by lymph node involve-
ment based on receipt of trastuzumab showed that patients 
with node positive tumours had improved 5-year DFS (53% 
to 93%; p < 0.001), and 5-year OS (50% to 83%; p < 0.001).
Conclusion: This study has shown that long-term cancer-
specific outcomes (i.e. DFS and not OS) were improved for 
patients with HER2-positive EBC who received adjuvant 
trastuzumab. This benefit was greater for HER2-positive EBC 
where (1) tumours ≥ 2.01 cm and/or (2) ipsilateral axillary 
lymph node involvement.
Introduction
Human Epidermal Growth Factor Receptor-2 (HER2), encod-
ed by the HER2/neu proto-oncogene, is a member of a trans-
membrane growth factor receptor family with tyrosine kinase 
activity. HER2 is amplified or overexpressed in approximately 
25% to 30% of tumours in patients with Female Breast Cancer 
(FBC), and is associated with less favourable cancer-specific out-
come [1-3]. Additionally, data has also shown that patients with 
HER2-positive breast cancer have an enhanced benefit for use 
of anthracycline-based chemotherapy over non-anthracycline-
based chemotherapy [4].
Trastuzumab (Herceptin ®; Genentech, San Francisco, CA) is 
a synthetic and recombinant humanised monoclonal antibody 
that binds to the extracellular domain of HER2. The action of 
this drug consequently blocks intracellular signalling and inhibits 
cell proliferation in HER2-dependent tumours [3]. Trastuzumab 
was approved for clinical use in 1998 in tandem with chemo-
therapy as a first-line treatment for HER2-positive metastatic 
breast cancer; where it was found to improve Overall Survival 
(OS) more than chemotherapy alone [5]. Subsequently, the in-
dication was extended to include use in the adjuvant setting fol-
lowing chemotherapy in patients with high-risk HER2-positive 
EBC [3,5,6]. With this new clinical indication, it was shown to 
improve Disease-Free Survival (DFS) and Overall Survival (OS) 
when compared to chemotherapy alone for patients with HER2-
positive EBC.
Breast cancer research into therapeutics has developed at a 
rapid pace over the last few decades. Recent discoveries have 
afforded the delivery of individualised treatment options, and 
also increased long-term survival for patients with FBC. Clinical, 
demographic, and pathologic features (i.e. age, race, pathologic 
tumour size, histologic tumour type, axillary lymph node sta-
tus, standardised pathologic grade, hormone-receptor status, 
HER2-status, p53 mutation, and lympho-vascular invasion) are 
well accepted as established prognostic and/or predictive fac-
tors for the selection of systemic adjuvant therapy for EBC [4].
Recent reports have explored the survival benefit afforded by 
adjuvant trastuzumab for high-risk patients with HER2-positive 
EBC, and some pivotal studies have reviewed long-term follow-
up of efficacy data of adjuvant trastuzumab [7,8]. These all dem-
onstrate significant cancer-specific survival benefit seen with 
long-term follow-up, with an acceptable safety profile including 
relatively low levels of cardiac adverse events. Therefore, reduc-
ing cardiotoxicity has been highlighted as a key factor of future 
adjuvant trastuzumab treatment strategies, particularly in the 
elderly and in those who would achieve little benefit from treat-
ment [4].
This article reports the long-term follow-up data in female 
patients diagnosed with HER2-positive EBC (i.e. non-metastatic) 
that were referred and managed in a Medical Oncology Depart-
ment of a designated cancer centre, and correlated outcome 
based on receipt of adjuvant trastuzumab following chemo-
therapy. The primary objective was to determine if long-term 
cancer-specific outcome was improved with administration of 
adjuvant trastuzumab. Secondary objectives of this study were 
to document the incidence; demographics; histologic features; 
and adjuvant therapies offered to patients within our region.
Methods
Patient selection
The cohort under investigation involved only female patients 
diagnosed with HER2-positive EBC that were referred to Medi-
cal Oncology within the period 1st January 2001 to 31st Decem-
ber 2010. HER2 amplification or overexpression was assessed 
primarily in UHL. Any specimen with equivocal results was re-
viewed in a central verification laboratory in Dublin, Ireland. 
HER2-positive EBC was defined as:
A result on Immunohistochemical (IHC) analysis at UHL • 
(HercepTest, Dako Corporation) of 3+, in a range from 0 to 3+, 
or
Positive result on Fluorescence In Situ (FISH) analysis • 
of HER2 amplification (PathVysion, Abbott Molecular) for tu-
mours that were assessed at UHL as IHC 2+.
For the patients included in the cohort (Figure 1), the follow-
ing inclusion criteria were used:
Patient age at presentation ≥ 18 years,• 
Pathologic data available (i.e. histologic sub-type, tu-• 
mour grade of differentiation, oestrogen (ER) status, progester-
one (PgR) status, tumour size, number of lymph nodes harvest-
ed and positive lymph node count),
Availability of records of adjuvant systemic therapies • 
administered (i.e. trastuzumab, chemotherapy, and hormonal 
therapy),
Availability of records of locoregional treatment (i.e. • 
breast/axillary surgery, and radiation administered), and
Patients were reviewed by the Symptomatic Breast • 
Unit in UHL, via a combination of clinical appointments within 
Mid-Western Cancer Centre and General Practitioners, who re-
turned information on recurrence and survival status.
Exclusion criteria included: patients with HER2-negative EBC 
and metastatic disease (both confirmed by histologic and/or ra-
diologic examination).
Data collection
Data was derived from the Medical Oncology database, Uni-
versity Hospital Limerick (UHL) case records, UHL pathology re-
cords, UHL radiology reports, and UHL Breast Multi-Disciplinary 
Team (MDT) records.
Data analysis
Follow-up time was calculated from the date of first surgical 
intervention to the date of last follow-up or death. The median 
follow-up was 59.8 months (Interquartile Range (IQR): 37.1 to 
88.9 months).
Data was entered onto an Access database (Microsoft Corp, 
Redmond, WA). Information was collated and exported to Excel 
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(Microsoft Corp, Redmond, WA), where the data was cleaned. 
The final data set was anonymised (i.e. all personal identifiers 
were removed) and inputted into a statistical package (IBM 
SPSS Statistics for Mac, Version 22.0 (IBM Corp, Armonk, NY)). 
The cohort was analysed by applying descriptive statistics. Re-
sults from both groups (i.e. groups determined by receipt of 
adjuvant trastuzumab therapy) were compared to identify any 
differences. All variables were considered to be independent. χ2 
test was used for categorical data.
Life table survival curves were constructed using IBM SPSS 
Statistics for both DFS and OS. DFS was calculated as time be-
tween the histologic diagnosis to the time of first recurrence 
(proven histologically and/or radiologically). OS was calculated 
as the time between the histologic diagnosis and time of last 
contact or death (from both cancer and non-cancer causes). 
Survival curves were estimated with the Kaplan-Meier method.
Differences identified were considered significant if p < 0.05 
(2-tailed).
The study was approved by University Hospital Limerick 
(UHL) Research Ethics Committee (REC).
Results
1,041 patients with EBC were referred to the Medical Oncol-
ogy Department in UHL during the period under review. 660 
individual histologic samples had assessable HER2 test results. 
The prevalence rate for patients with HER2-positive EBC in UHL 
cohort was 14.1% (147/1,041) and among tested samples 22.3% 
(147/660).
Summary data
A total of 147 patients with invasive HER2-positive EBC were 
referred to the Medical Oncology Department in UHL within the 
study period. Median age at presentation was 55.0 years (IQR: 
45 to 62 years). Table 1 lists the demographic and adjuvant 
trastuzumab treatment characteristics. The majority of HER2-
positive EBC patients were noted to be predominantly married, 
mainly Caucasian, and a majority were diagnosed within the 
UHL region (comprising Counties Clare, Limerick, and North Tip-
perary).
The right-skewed age distribution is shown in Figure 2, where 
most of the patients were between 45 and 65 years of age.
Clinical and demographic data
Table 2 shows the clinical and demographic data for patients 
with HER2-positive EBC stratified by the administration of adju-
vant trastuzumab. It was noted that patient’s ≥ 65 years were 
less likely to receive adjuvant trastuzumab (RR: 0.32; 95%CI: 
0.14 to 0.73; p < 0.001). No other significant differences were 
noted between the two groups.
Pathological data
Table 3 is a summary of the pathological data for UHL cohort, 
stratified according to administration of trastuzumab therapy. It 
was shown that among patients having adjuvant trastuzumab 
therapy, there was greater likelihood of: lobular and mixed car-
cinomas (RR: 1.49; 95%CI: 0.93 to 2.37; p = 0.094); higher grade 
of histologic differentiation (RR: 1.30; 95%CI: 0.98 to 1.74; p = 
0.074); negative PgR status (RR: 1.64; 95%CI: 1.19 to 2.28; p = 
0.003); and lymph node metastases with N1 disease (RR: 1.97; 
95%CI: 1.31 to 2.96; p = 0.001), N2 disease (RR: 1.79; 95%CI: 
1.13 to 2.83; p = 0.013), and N3 disease (RR: 1.90; 95%CI: 1.22 
to 2.96; p = 0.004).
Adjuvant treatment data
Table 4 is a summary of the adjuvant treatment data for UHL 
cohort, stratified according to administration of adjuvant tras-
tuzumab therapy. It was shown that among patients having ad-
juvant trastuzumab therapy, there was more likelihood of hav-
ing, adjuvant chemotherapy (RR: 6.56; 95%CI: 1.76 to 24.49; p 
= 0.005), and adjuvant radiation therapy (RR: 1.58; 95%CI: 0.99 
to 2.52; p = 0.054).
Survival analysis
Overall
Figure 3 and Figure 4 show the Kaplan-Meier estimates for 
DFS and OS stratified based on administration of adjuvant tras-
tuzumab therapy. There was a trend towards improved DFS (p 
= 0.056) with adjuvant trastuzumab, while no such trend was 
seen for OS (p = 0.263). Additionally, these estimates also dem-
onstrate that long-term benefit of adjuvant trastuzumab does 
not extend beyond 5-years of treatment; this was more evident 
in the OS plot.
Calculations for the patients with HER2-positive EBC that 
had adjuvant trastuzumab were revealed to have significant 
improvement in 5-year DFS from 75% to 91% (p = 0.024), and 
non-significant trend for improved 5-year OS from 74% to 80% 
(p = 0.103) Table 5.
Tumour size
Figure 5 shows the Kaplan-Meier estimates for DFS and OS 
stratified by administration of trastuzumab therapy and also 
for tumour size. For tumours greater than 2.01cm, there was a 
trend for better DFS (p = 0.070). No other significant differences 
in outcome were noted.
Subgroup calculations for patients with HER2-positive EBC 
that had adjuvant trastuzumab were performed. Stratification 
by tumour size has shown that that for tumours ≥ 2.01cm had 
a significant improvement in 5-year DFS from 66% to 88% (p = 
0.031), and a non-significant trend for improvement in 5-year 
OS from 66% to 79% 9 (p = 0.134) Table 6.
Figure 6 shows the Kaplan-Meier estimates for DFS and OS 
stratified by administration of trastuzumab therapy and also 
for lymph node involvement. For patients with node-positive 
HER2-positive EBC, DFS (p < 0.001) and OS (p = 0.001) were 
improved with administration of trastuzumab. There were no 
significant improvements seen for patients with node-negative 
HER-positive EBC.
Further subgroup calculations for patients with HER2-pos-
itive EBC that had adjuvant trastuzumab were undertaken. 
Stratification by lymph node involvement has shown that pa-
tients with node-positive disease had significant improvement 
in 5-year DFS from 53% to 93% (p < 0.001), and 5-year OS from 
50% to 83% (p < 0.001) Table 7.
Discussion
Several pivotal studies have demonstrated that the addition 
of adjuvant trastuzumab therapy for 1 year to standard che-
motherapy can significantly improve DFS and OS versus stan-
dard chemotherapy alone [5,6,9]. This present study reports 
on long-term follow-up and outcome, based on receipt of ad-
juvant trastuzumab amongst patients with HER2-positive EBC. 
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Results from the UHL-based cohort have shown that 5-year DFS 
(75% to 91%; p = 0.024) were improved with administration of 
adjuvant trastuzumab, with a non-statistically significant trend 
for 5-year OS (74% to 80%; p = 0.103). These findings are not 
consistent with published reports, where adjuvant trastuzumab 
conferred both DFS and OS advantage. This might be related to 
the non-randomised and retrospective nature of study design 
employed, as it included all patients with HER2-positive EBC ir-
respective of their eligibility to undergo biological therapy with 
trastuzumab.
On subgroup analysis, varied outcome was observed with 
administration of adjuvant trastuzumab in patients with HER2-
positive EBC tumours based on pathologic tumour size. In tu-
mours ≥ 2.01cm have shown that 5-year DFS (66% to 88%; p = 
0.031) not 5-year OS (66% to 79%; p = 0.134) revealed improved 
outcome. The literature has reported differential outcome 
based on tumour size. Adjuvant trastuzumab has been shown 
to be beneficial for tumours > 1.00cm, however smaller studies 
have revealed an absolute risk reduction by 2 to 7% irrespective 
of tumour size [5,10].
Further subgroup analysis (using log rank to compare esti-
mates) has revealed that HER2-positive lymph node involve-
ment had improved 5-year DFS (53% to 93%; p < 0.001) and 
5-year OS (50% to 83%; p < 0.001). This is supported by the lit-
erature demonstrating a greater benefit for patients with node-
positive HER2-positive EBC receiving trastuzumab [5,6,11]. In 
general, the DFS and OS indices produced for this cohort of 
patients with HER2-psoitive EBC who received adjuvant trastu-
zumab were lower than published results. However, the pres-
ent study included “all-comers”, and again due its retrospective 
design had a greater proportion of older patients (some with 
medical co-morbidities precluding them from administration of 
trastuzumab), as well as patient with larger tumours and axil-
lary lymph node involvement.
The clinical and demographic data shows that the median 
age for UHL HER2-positive cohort was 55 years. This was great-
er than 49 years reported in the HERA trial, but comparable to 
patient cohort in PHARE trial [5,9]. This variation may be due 
to younger patients more commonly being enrolled into clini-
cal trials. In this project, patients receiving trastuzumab had a: 
young median age (54 years versus 57 years); and lower propor-
tion ≥65 years (6% versus 28%; p = 0.007) when compared to 
patients not receiving adjuvant trastuzumab. All other param-
eters were comparable between the groups. The majority of pa-
tients were Caucasian, and this demographic finding was similar 
to the published reports [5,6].
The pathological data for patients in our cohort receiving 
adjuvant trastuzumab had: higher proportion of Grade III HER2-
positive EBC (48% versus 31%; p = 0.074); higher PgR negative 
rates (65% versus 39%; p = 0.003); and higher proportions of 
lymph node involvement (75% versus 44%; p < 0.001), when 
compared to patients not receiving adjuvant trastuzumab. 
These findings were not unexpected, as they are all indicative 
of less favourable prognosis, which would warrant the addition 
of trastuzumab to adjuvant systemic intervention [3,5,6,9].
This data set also highlighted those patients receiving adju-
vant trastuzumab had: higher proportions undertaking adjuvant 
chemotherapy (95% versus 51%; p = 0.005); and higher propor-
tions having radiation therapy (85% versus 64%; p = 0.054), 
when compared with patients not having adjuvant trastuzum-
ab; again indicating a patient population with less favourable 
pathologic features. These findings were comparable to results 
in the literature [6,9].
A strength of this study is that the clinical data was derived 
from 10 years of primary data, which was specifically assembled 
to review the long-term outcome of adjuvant trastuzumab in 
patients with HER2-postive EBC. Most reports in the literature 
are based on cohorts that are recruited for RCTs, which may not 
be representative of the patient cohort receiving trastuzumab 
in the clinical setting. Another strength is related to the com-
pleteness of the data collected. This is linked to the availabil-
ity of all the relevant data in UHL. In addition, the number of 
unique patients identified for this cohort adds to the strength 
of the study.
The study has some limitations. The first limitation is related 
to the relatively small numbers within the cohort from a single 
specialised cancer centre unit, which was associated with non-
randomised consecutive patient selection. This was somewhat 
overcome by having comprehensive access to all cohort data. 
Another limitation is related to eligibility for treatment with 
trastuzumab, as not all patients with HER2-positive EBC re-
ceived the drug. This is due to evidence that purports that it 
only be offered to patients with less favourable pathologic fea-
tures (i.e. tumour size >2cm, poorly differentiated histologic le-
sions, and associated lymph node involvement). This inherently 
means that patients who receive the agent have less favourable 
prognosis; but despite this, it has been shown that adjuvant 
trastuzumab administration in patients with HER2-positive EBC 
resulted in improved outcome. This highlights the translation 
of clinical trials’ results into relevant the ‘real world’ setting, 
where patients are not super-selected. Additionally, those who 
did not receive trastuzumab might also have unknown differ-
ences (i.e. non-histologic features including and not limited to 
medical co-morbidities, cardiac issues) that might have impact 
on cancer-specific outcome.
Conclusion
This study was to determine and quantify the long-term can-
cer-specific outcome in patients with HER2-positive EBC, based 
on the administration of adjuvant trastuzumab therapy. Statisti-
cally significant improvements in DFS and not OS were shown 
to improve with adjuvant trastuzumab. Additionally, it was re-
vealed that cancer-specific outcomes were improved in patients 
with HER2-positive EBC where (1) tumours were ≥ 2.01cm and/
or (2) lymph node involvement.
Clinical practice points
Adjuvant trastuzumab therapy is beneficial for patients • 
with HER2-positive EBC
Greatest benefit was seen in patients with high-risk • 
features (i.e. tumours were ≥ 2.01cm and/or lymph node in-
volvement), and
Benefits of adjuvant trastuzumab appear to be sus-• 
tained.
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Figures
Figure 1: Flowchart describing eligible patients in UHL cohort.
Figure 2: Age distribution for UHL HER2-positive cohort.
Figure 3: DFS in UHL cohort based on administration of tras-
tuzumab.
Figure 4: OS in UHL cohort based on administration of trastu-
zumab.
Figure 5: show DFS and OS in UHL HER2-positive cohort based 
on tumour size.
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Figure 6: Show DFS and OS in UHL HER2-positive cohort based on lymph 
node involvement.
HER2-positive cohort in UHL Data completeness
Number 147
Age 100%
Median• 
Interquartile range• 
55.0 years
45.0 to 62.0 years
Marital status 99.3%
Single• 
Married• 
Widowed• 
Divorced• 
Not specified• 
26 (17.7%)
103 (70.1%)
14 (9.5)
3 (2.0%)
1 (0.7%)
Region of diagnosis 100%
Inside UHL region• 
Outside UHL region• 
130 (88.4%)
17 (11.6%)
Ethnicity 88.4%
Caucasian• 
Non-Caucasian• 
Not specified• 
128 (87.1%)
2 (1.4%)
17 (11.6)
Adjuvant trastuzumab 99.3%
Offered therapy• 
Administered• 
Not administered• 
Not offered therapy• 
Not specified• 
86 (58.5%)
80/86 (93.0%)
6/86 (7.0%)
60 (40.8%)
1 (0.7%)
Table 1: Summary data for UHL HER2-positive cohort.
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Table 2: Summary of clinical and demographic data for UHL HER2-positive cohort.
Adjuvant trastuzumab administered
Relative risk
95% Confidence 
interval
p-value
Yes No
Age
Median• 
IQR (years)• 
≤ 44 years• 
45 to 54 years• 
55 to 64 years• 
≥ 65 years• 
54 years
48.0 to 67.0
22 (28%)
19 (24%)
34 (43%)
5 (6%)
57 years
43.0 to 60.8
12 (18%)
16 (24%)
20 (30%)
19 (28%)
Reference 
0.83
0.97
0.32
0.57 to 1.24
0.71 to 1.34
0.14 to 0.73
0.381
0.868
< 0.001
Ethnicity 
Caucasian• 
Non-Caucasian• 
Not specified• 
75 (94%)
0 (0%)
5 (6%)
53 (79%)
2 (3%)
12 (18%)
Reference
0.28
0.50
0.02 to 3.59
0.24 to 1.06
0.331
0.072
Smoking status
Current• 
Former• 
Never• 
Not specified• 
13 (16%)
28 (35%)
34 (43%)
5 (6%)
9 (13%)
17 (25%)
29 (43%)
12 (18%)
1.09
1.15
Reference
0.55
0.72 to 1.66
0.84 to 1.59
0.25 to 1.18
0.669
0.387
0.123
***Percentages may not add to 100%, as they have been rounded.
Table 3: Summary of pathological data for UHL HER2-positive cohort.
Adjuvant trastuzumab administered
Relative risk
95% Confidence 
interval
p-value
Yes No
Histology
Ductal carcinoma• 
Lobular carcinoma• 
Mixed carcinoma• 
Other carcinoma• 
72 (90%)
4 (5%)
4 (5%)
0 (0%)
62 (93%)
1 (1%)
1 (1%)
3 (4%)
Reference
1.49
1.49
0.23
0.93 to 2.37
0.93 to 2.37
0.02 to 3.13
0.094
0.094
0.271
Grade of differentiation
I – Well• 
II – Moderate• 
III – Poor• 
Not specified• 
0 (0%)
40 (50%)
38 (48%)
2 (3%)
2 (3%)
41 (61%)
21 (31%)
3 (4%)
0.34
Reference
1.30
0.81
0.03 to 4.28
0.98 to 1.74
0.27 to 2.42
0.402
0.074
0.706
Oestrogen (ER) status
Positive• 
Negative• 
39 (49%)
41 (51%)
41 (61%)
26 (39%)
Reference
1.26 0.93 to 1.69 0.131
Progesterone (PgR) status
Positive• 
Negative• 
28 (35%)
52 (65%)
41 (61%)
26 (39%)
Reference
1.64 1.19 to 2.28 0.003
Tumour size
≤ 1.00 cm• 
1.01 to 2.00 cm• 
≥ 2.01 cm• 
12 (16%)
15 (20%)
49 (64%)
8 (13%)
20 (31%)
36 (56%)
Reference
1.56
1.08
0.76 to 3.20
0.48 to 2.42
0.232
0.848
Lymph node (LN) status
N0: 0 LN• 
N1: 1 to 3 LN• 
N2: 4 to 9 LN• 
N3: ≥ 10 LN• 
20 (25%)
26 (33%)
16 (20%)
17 (22%)
35 (56%)
11 (17%)
9 (14%)
8 (13%)
Reference
1.97
1.79
1.90
1.31 to 2.96
1.13 to 2.83
1.22 to 2.96
0.001
0.013
0.004
MedDocs Publishers
8Annals of Breast Cancer
***Percentages may not add to 100%, as they have been rounded.
Table 4: Summary adjuvant treatment for UHL HER2-positive cohort.
Adjuvant trastuzumab administered
Relative risk
95% Confidence 
interval
p-value
Yes No
Surgical intervention
Breast conserving surgery• 
Mastectomy• 
No surgery• a
23 (29%)
54 (68%)
3 (4%)
23 (34%)
41 (61%)
3 (5%)
1.00
1.13
Reference
0.43 to 2.34
0.50 to 2.58
1.000
0.759
Axillary intervention
Axillary nodal clearance• 
Axillary nodal sampling• 
Sentinel lymph node biopsy• 
No surgery• b
70 (88%)
1 (1%)
8 (10%)
1 (1%)
54 (81%)
4 (6%)
6 (9%)
3 (5%)
2.26
0.80
2.29
Reference
0.41 to 12.41
0.07 to 9.18
0.39 to 13.25
0.349
0.858
0.356
Chemotherapy
Yes• 
No• c
Offered but declined• d
Not specified• 
76 (95%)
2 (3%)
2 (3%)
0 (0%)
34 (51%)
17 (25%)
15 (22%)
1 (2%)
6.56
Reference
1.12
2.00
1.76 to 24.49
0.18 to 7.09
0.14 to 28.76
0.005
0.906
0.610
Hormonal therapy
Yes• 
No• 
Offered but declined• 
40 (50%)
40 (50%)
0 (0%)
41 (61%)
25 (37%)
1 (2%)
0.80
Reference
0.41
0.60 to 1.08
0.04 to 4.52
0.140
0.465
Radiation therapy
Yes• 
No• 
Not specified• 
68 (85%)
12 (15%)
0 (0%)
43 (64%)
19 (28%)
5 (8%)
1.58
Reference
0.21
0.99 to 2.52
0.01 to 3.14
0.054
0.260
***Percentages may not add to 100%, as they have been rounded.
a:2 patients had no macroscopic disease and did not have any definitive breast surgery, and 1 patient with macroscopic 
disease with advanced multiple sclerosis (Available URL: http://cancer-therapy.org/CT/v8/A/4_Bahrum_et_al_10-23.pdf (Date 
accessed: 12th December 2016)).
b:1 patient with macroscopic disease with advanced multiple sclerosis.
c:1 patient with macroscopic disease with advanced multiple sclerosis, and 1 patient with co-morbidities that precluded che-
motherapy.
d:2 patients who declined chemotherapy, but with high-risk HER2-positive that warranted systemic therapy.
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Table 5: Survival indices for UHL HER2-positive cohort.
Adjuvant trastuzumab administered
Yes No
Disease-free survival N = 80 N = 67
1-year• 
2-year• 
5-year• 
8-year• 
100%
99%
91%
75%
97%
88%
75%
62%
Overall survival N = 80 N = 67
1-year• 
2-year• 
5-year• 
8-year• 
100%
99%
80%
66%
97%
88%
74%
60%
Table 6: Survival indices for UHL HER2-positive cohort.
Adjuvant trastuzumab administered
Yes No
Disease-free survival: ≤ 1.00cm N = 12 N = 8
1-year• 
2-year• 
5-year• 
8-year• 
100%
100%
100%
50%
100%
100%
83%
83%
Overall survival: ≤ 1.00cm N = 12 N = 8
1-year• 
2-year• 
5-year• 
8-year• 
100%
100%
100%
50%
100%
100%
83%
83%
Disease-free survival: 1.01 to 
2.00cm
N = 15 N = 20
1-year• 
2-year• 
5-year• 
8-year• 
100%
100%
86%
86%
1005
95%
89%
71%
Overall survival: 1.01 to 2.00cm N = 15 N = 20
1-year• 
2-year• 
5-year• 
8-year• 
100%
100%
75%
75%
100%
95%
84%
67%
Disease-free survival: ≥ 2.01cm N = 49 N = 36
1-year• 
2-year• 
5-year• 
8-year• 
100%
98%
88%
72%
97%
83%
66%
54%
Overall survival: ≥ 2.01cm N = 49 N = 36
1-year• 
2-year• 
5-year• 
8-year• 
100%
98%
79%
64%
97%
83%
66%
54%
Table 7: Survival indices for UHL HER2-positive cohort strat-
ified by lymph node involvement.
Adjuvant trastuzumab administered
Yes No
Disease-free survival: node 
negative
N = 21 N = 39
1-year• 
2-year• 
5-year• 
8-year• 
100%
95%
84%
56%
97%
95%
92%
82%
Overall survival: node 
negative
N = 21 N = 39
1-year• 
2-year• 
5-year• 
8-year• 
100%
95%
70%
47%
97%
95%
92%
82%
Disease-free survival: node 
positive
N = 59 N = 28
1-year• 
2-year• 
5-year• 
8-year• 
100%
100%
93%
80%
96%
79%
53%
40%
Overall survival: node 
positive
N = 59 N = 28
1-year• 
2-year• 
5-year• 
8-year• 
100%
100%
83%
71%
96%
79%
50%
38%
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